Literature DB >> 21239799

Long-term physiological side effects after allogeneic bone marrow transplantation.

Mohamad Mohty1, Jane F Apperley.   

Abstract

Allogeneic bone marrow transplantation (allo-BMT) or stem cell transplantation has the potential to cure a significant proportion of patients with otherwise fatal diseases. At present, immediate survival is no longer the sole concern after allo-BMT, because many patients can survive the acute complications of the procedure and remain free of their original disease for several years. Although long-term allo-BMT survivors generally enjoy good health, for many others cure or control of the underlying disease is not accompanied by full restoration of health. The long-term physiologic effects after allo-BMT include nonmalignant organ or tissue dysfunction; changes in quality of life; infections related to delayed, or abnormal, immune reconstitution; and secondary cancers. These long-term complications and the features of chronic graft-versus-host disease (GVHD) symptoms are heterogeneous in nature, time of onset, duration, and severity. The underlying origin of these complications is often multifactorial, with chronic GVHD being the most challenging risk factor. The main aims of this review are to present transplant physicians and health care providers with an overview of these malignant and nonmalignant late complications, with a special focus on chronic GVHD. A close partnership between the transplant center, organ-specific specialties, and local primary care providers is a key component of preventive medicine. The patient can play a major role through engagement in health maintenance behaviors.

Entities:  

Mesh:

Year:  2010        PMID: 21239799     DOI: 10.1182/asheducation-2010.1.229

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  12 in total

Review 1.  An experimental approach to the generation of human embryonic stem cells equivalents.

Authors:  Katarzyna Skowron; Marcin Tomsia; Piotr Czekaj
Journal:  Mol Biotechnol       Date:  2014-01       Impact factor: 2.695

2.  To RIC or not to RIC: that is the question.

Authors:  M Mohty; F Malard
Journal:  Leukemia       Date:  2015-04-14       Impact factor: 11.528

3.  The quest for transplantation tolerance: have we finally sipped from the cup?

Authors:  James F Markmann; Tatsuo Kawai
Journal:  Sci Transl Med       Date:  2012-03-07       Impact factor: 17.956

Review 4.  Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients.

Authors:  Bernard Lawrence Marini; Sung Won Choi; Craig Alan Byersdorfer; Simon Cronin; David G Frame
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-20       Impact factor: 5.742

Review 5.  Pediatric Vulvovaginal Graft-Versus-Host Disease: A Retrospective Cohort Study and Literature Review.

Authors:  Tazim Dowlut-McElroy; Stephanie Shin; Elizabeth Stepanek; David Jacobsohn; Veronica Gomez-Lobo
Journal:  J Pediatr Adolesc Gynecol       Date:  2022-04-25       Impact factor: 2.046

Review 6.  How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.

Authors:  Samantha M Jaglowski; Bruce R Blazar
Journal:  Blood Adv       Date:  2018-08-14

Review 7.  Late Complications of Allogenic Stem Cells Transplantation in Leukaemia.

Authors:  Sharmilla Kanagasundram; Farhanaz Amini
Journal:  Tissue Eng Regen Med       Date:  2018-09-06       Impact factor: 4.169

8.  Acellular bone marrow extracts significantly enhance engraftment levels of human hematopoietic stem cells in mouse xeno-transplantation models.

Authors:  Kazem Zibara; Rima Hamdan; Leila Dib; Steen Sindet-Pedersen; Mohamed Kharfan-Dabaja; Ali Bazarbachi; Marwan El-Sabban
Journal:  PLoS One       Date:  2012-07-02       Impact factor: 3.240

Review 9.  Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT).

Authors:  Sharon Elad; Judith E Raber-Durlacher; Michael T Brennan; Deborah P Saunders; Arno P Mank; Yehuda Zadik; Barry Quinn; Joel B Epstein; Nicole M A Blijlevens; Tuomas Waltimo; Jakob R Passweg; M Elvira P Correa; Göran Dahllöf; Karin U E Garming-Legert; Richard M Logan; Carin M J Potting; Michael Y Shapira; Yoshihiko Soga; Jacqui Stringer; Monique A Stokman; Samuel Vokurka; Elisabeth Wallhult; Noam Yarom; Siri Beier Jensen
Journal:  Support Care Cancer       Date:  2014-09-05       Impact factor: 3.603

10.  Novel Treatment of Chronic Graft-Versus-Host Disease in Mice Using the ER Stress Reducer 4-Phenylbutyric Acid.

Authors:  Shin Mukai; Yoko Ogawa; Fumihiko Urano; Chie Kudo-Saito; Yutaka Kawakami; Kazuo Tsubota
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.